Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
暂无分享,去创建一个
Trista K. Hinz | Lynn E. Heasley | R. Doebele | L. Heasley | B. Helfrich | K. Ware | Robert C. Doebele | Kathryn E. Ware | Marianne E. Marshall | Lydia R. Heasley | Lindsay Marek | Paula Hercule | Barbara A. Helfrich | L. Marek | T. Hinz | Paula Hercule | L. Heasley | Lydia R. Heasley | Lynn E. Heasley | Lindsay A. Marek
[1] H. Kuhn,et al. Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines. , 2004, Lung cancer.
[2] J. Dancey. Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. , 2004, Cancer cell.
[3] A. Chang,et al. Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer , 2008, International journal of medical sciences.
[4] L. Chandler,et al. Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines , 1999, International journal of cancer.
[5] Ho-Yyoung Lee,et al. Resistance to epidermal growth factor receptor-targeted therapy. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[6] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[7] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[8] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[9] Qiongyu Chen,et al. Nuclear Factor Y Is Required for Basal Activation and Chromatin Accessibility of Fibroblast Growth Factor Receptor 2 Promoter in Osteoblast-like Cells*S⃞ , 2009, Journal of Biological Chemistry.
[10] V. P. Eswarakumar,et al. Cellular signaling by fibroblast growth factor receptors. , 2005, Cytokine & growth factor reviews.
[11] L. Ellis,et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[13] T. Mohr,et al. Evidence for a role of FGF‐2 and FGF receptors in the proliferation of non‐small cell lung cancer cells , 1999, International journal of cancer.
[14] A. Xu,et al. Receptor tyrosine kinase coactivation networks in cancer. , 2010, Cancer research.
[15] P. Bunn,et al. Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells , 2009, Molecular Pharmacology.
[16] R. Devlin,et al. Transcriptional profiling of mucociliary differentiation in human airway epithelial cells. , 2007, American journal of respiratory cell and molecular biology.
[17] W. Berger,et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition , 2008, Molecular Cancer Therapeutics.
[18] Stuart Thomson,et al. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy , 2008, Clinical & Experimental Metastasis.
[19] P. Jänne,et al. Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.
[20] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] E. Dmitrovsky,et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] M. Humbert,et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. , 2009, The Journal of clinical investigation.
[23] M. Stack,et al. Epidermal Growth Factor Receptor Inhibition Promotes Desmosome Assembly and Strengthens Intercellular Adhesion in Squamous Cell Carcinoma Cells* , 2004, Journal of Biological Chemistry.
[24] S. Steinberg,et al. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. , 1993, Cancer research.
[25] N. Ahn,et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. , 1994, Science.
[26] R. Lotan,et al. Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer , 2008, Clinical Cancer Research.
[27] K. Longmuir,et al. Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. , 1994, The Journal of clinical investigation.
[28] D. Yee,et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. , 2008, The Journal of clinical investigation.
[29] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[30] Jeffrey A Whitsett,et al. Intrinsic and innate defenses in the lung: intersection of pathways regulating lung morphogenesis, host defense, and repair. , 2002, The Journal of clinical investigation.
[31] K. Luk,et al. RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation. , 2005, Bioorganic & Medicinal Chemistry.
[32] B. Druker,et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. , 2003, Blood.
[33] P. Bunn,et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma , 2007, Molecular Cancer Therapeutics.
[34] Chan Zeng,et al. Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines , 2006, Molecular Cancer Research.
[35] J. Haveman,et al. Clonogenic assay of cells in vitro , 2006, Nature Protocols.